| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Drug Targeting Laboratory, Imperial Cancer Research Fund, P. O. Box 123, Lincoln's Inn Fields, London WC2A 3PX [P. E. T., P. M. W., P. P. K., M. G. R., A. N. F. B., G. J. W., D. C. B.], and Drug Development Section, Institute of Cancer Research, Clifton Avenue, Sutton, Surrey SM2 5PX [D. R. N.] England
A monoclonal anti-Thy-1.1 antibody (OX7) was coupled to either native or chemically deglycosylated ricin A-chain (dgA) using one of two different cross-linking agents. One cross-linker, N-succinimidyloxycarbonyl-
-methyl-
-(2-pyridyldithio)toluene (SMPT), generates a sterically hindered disulfide bond which is relatively resistant to reduction, whereas the other, 2-iminothiolane hydrochloride, generates an unhindered disulfide bond with greater lability. A two-compartment pharmacokinetic model was used to analyze the blood levels of each immunotoxin and its breakdown product (free antibody) after i.v. injection into mice. Immunotoxins prepared with SMPT broke down in vivo 6.3-fold more slowly than those prepared with 2-iminothiolane hydrochloride, and immunotoxins containing native A-chain were cleared 2- to 3-fold more rapidly from the bloodstream than those containing dgA. As a result, 24 h after injection, 16% of the OX7-SMPT-dgA remained in the blood as compared with 0.4 to 2.5% of the other immunotoxins. Immunotoxins prepared with dgA were about 3-fold more toxic to mice than those prepared with native A-chain, whereas immunotoxins prepared with SMPT were only slightly more toxic than those prepared with 2-iminothiolane hydrochloride. When equivalent toxic doses of the immunotoxins were administered i.v. to mice which had been given injections of Thy-1.1+ AKR-A/2 lymphoma cells, the OX7-SMPT-dgA gave the best antitumor effect. A dose equivalent to one-seventh of the median lethal dose extended the survival time of the animals by the extent expected if 99.999% of the tumor cells had been eradicated. Furthermore, the tumors that did develop in the mice treated with OX7-SMPT-dgA were mutants which were resistant to all the immunotoxins. Some of the mutants were deficient in Thy-1.1 whereas others were not. In conclusion, both the use of the SMPT cross-linker and deglycosylation of the A-chain significantly improve the therapeutic index of the immunotoxins in AKR-A/2 tumor-bearing mice.
1 To whom requests for reprints should be addressed.
2 Present address: Imperial Chemical Industries PLC, Pharmaceuticals Division, CTL Building, Alderley Park, Macclesfield, Cheshire SK10 4TJ, England.
Received 5/16/88. Revised 8/ 9/88. Accepted 8/15/88.
This article has been cited by other articles:
![]() |
C. D. Austin, X. Wen, L. Gazzard, C. Nelson, R. H. Scheller, and S. J. Scales Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates PNAS, December 13, 2005; 102(50): 17987 - 17992. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schnell, P. Borchmann, J. O. Staak, J. Schindler, V. Ghetie, E. S. Vitetta, and A. Engert Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma Ann. Onc., May 1, 2003; 14(5): 729 - 736. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schnell, O. Staak, P. Borchmann, C. Schwartz, B. Matthey, H. Hansen, J. Schindler, V. Ghetie, E. S. Vitetta, V. Diehl, et al. A Phase I Study with an Anti-CD30 Ricin A-Chain Immunotoxin (Ki-4.dgA) in Patients with Refractory CD30+ Hodgkin's and Non-Hodgkin's Lymphoma Clin. Cancer Res., June 1, 2002; 8(6): 1779 - 1786. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Q. Xia, J. Wang, and W.-C. Shen Hypoglycemic Effect of Insulin-Transferrin Conjugate in Streptozotocin-Induced Diabetic Rats J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 594 - 600. [Abstract] [Full Text] |
||||
![]() |
M W J d. Brok, G C de Gast, J H M Schellens, and J H Beijnen Targeted toxins Journal of Oncology Pharmacy Practice, December 1, 1999; 5(4): 149 - 165. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |